SavedAdd your journal

Journals / European Journal of Rheumatology / 2014 / Cilt: 1 - Sayı: 2

Romatoid artritte ve ankilozan spondilitte hepatit B ve C enfeksiyonlarının prevalansı: Ülke çapında çok merkezli bir çalışma

Neslihan YILMAZ
Birol BAYSAL
Sema YILMAZ
Umut KALYONCU
Ömer KARADAĞ
Nurdan TÖZÜN
Timuçin KAŞİFOĞLU
Ayten YAZICI
Gezmiş KİMYON
Hakan TEMİZ
Pages
51–54
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the RA group, both HBsAg and anti-HCV positive patients were older than negative ones (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Immunosuppressive therapies, especially tumor necrosis factor-? inhibitors, are frequently used in treatment of rheumatoid arthritis (RA) and ankylosing spondylitis (AS).
📊
Key Findings & Data:Material and Methods: A group of 1517 RA and 886 AS consecutive patients followed by six different rheumatology outpatient clinics of Turkey were recruited in this study.
💡
Conclusion & Impact:In the RA group, both HBsAg and anti-HCV positive patients were older than negative ones (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: Immunosuppressive therapies, especially tumor necrosis factor-? inhibitors, are frequently used in treatment of rheumatoid arthritis (RA) and ankylosing spondylitis (AS). These therapies can induce viral reactivation in concurrent hepatitis B virus (HBV)- or hepatitis C virus (HCV)- positive patients. On the other hand, the prevalence of HBV and HCV infections is not exactly known in RA and AS patients. The aim of this study was to investigate the prevalence of HBV and HCV infections in RA and AS patients. Material and Methods: A group of 1517 RA and 886 AS consecutive patients followed by six different rheumatology outpatient clinics of Turkey were recruited in this study. The prevalence of HBV surface antigen (HBsAg) and HCV antibody (anti-HCV) were retrospectively investigated. Results: The mean age was 49.0±13.2 years in RA and 37.3±10.5 years in AS patients. HBsAg prevalence was 35 (2.3%) in RA and 27 (3%) in AS patients. Anti-HCV prevalence was 17 (1.1%) and 10 (1.1%), respectively. In the RA group, both HBsAg and anti-HCV positive patients were older than negative ones (p

Özet

Amaç: İmmünosupresif tedaviler, özellikle tümör nekroz faktörü-alfa inhibitörleri, romatoid artrit (RA) ve ankilozan spondilit (AS) tedavisinde sıklıkla kullanılmaktadır. Bu tedaviler, hepatit B virüsü (HBV) ya da hepatit C virüsü (HCV) pozitif hastalarda eş zamanlı olarak viral reaktivasyonu indükleyebilir. Öte yandan, RA ve AS hastalarında HBV ve HCV enfeksiyonlarının prevalansı tam olarak bilinmemektedir. Bu çalışmanın amacı, RA ve AS hastalarında HBV ve HCV enfeksiyonlarının prevalansını araştırmaktı.Materyal ve Metot: Bu çalışmaya Türkiye'nin altı farklı romatoloji polikliniğinde takip edilen 1517 RA ve 886 AS hastası ardışık olarak alındı. HBV yüzey antijeni (HBsAg) ve HCV antikoru (anti-HCV) prevalansları retrospektif olarak değerlendirildi.Bulgular: Ortalama yaş RA hastalarında 49.0±13.2 yıl ve AS hastalarında 37.3±10.5 yıldı. HBsAg prevalansı RA hastalarında 35 (%2.3) ve AS hastalarında 27 (%3) idi. Anti-HCV prevalansı sırasıyla 17 (%1.1) ve 10 (%1.1) idi. RA grubunda, hem HBsAg ve hem de anti-HCV pozitif hastalar negatif olan hastalardan daha yaşlıydı (p

🔖

Cite This Article

YILMAZ, N., BAYSAL, B., YILMAZ, S., KALYONCU, U., KARADAĞ, Ö., TÖZÜN, N., KAŞİFOĞLU, T., YAZICI, A., KİMYON, G., TEMİZ, H. (2022). Romatoid artritte ve ankilozan spondilitte hepatit B ve C enfeksiyonlarının prevalansı: Ülke çapında çok merkezli bir çalışma. European Journal of Rheumatology, Cilt: 1 - Sayı: 2, 51–54. https://ajindex.com/articles/500902

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Oliver JE, Silman AJ. Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol 2006; 35: 169-74. [CrossRef] 2. Hoovestol RA, Mikuls TR. Environmental exposures and rheumatoid arthritis risk. Curr Rheumatol Rep 2011; 13: 431-9. [CrossRef] 3. Gaston JS. Infection in the etiology of spondyloarthropathies. Clin Med 2001; 1: 104-7. [CrossRef] 4. Girschick HJ, Guilherme L, Inman RD, Latsch K, Rihl M, Sherer Y, et al. Bacterial triggers and autoimmune rheumatic diseases. Clin Exp Rheumatol 2008; 26: 12-7. 5. Vassilopoulos D, Calabrese LH. Virally associated arthritis 2008: clinical, epidemiologic and pathophysiologic considerations. Arthritis Res Ther 2008; 10: 215. [CrossRef] 6. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev 2006; 28: 112-25. [CrossRef] 7. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1-16. [CrossRef] 8. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-9. [CrossRef] 9. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-? theraphy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006; 45: 1294-7. [CrossRef] 10. Pyrpasopoulou A, Douma S, Vassiliadis T, Chatzimichailidou S, Triantafyllou A, Aslanidis S. Reactivation of chronic hepatitis B virus infection following rituximab administration for rheumatoid arthritis. Rheumatol Int 2011; 31: 403-4. [CrossRef] 11. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84. [CrossRef] 12. Tozun N, Ozdoğan O, Cakaloglu Y, İdılman R, Karasu Z, Akarca U, et al. Nationwide Prevalence Study and Risk Factors for Hepatitis A, B, C and D Infections in Turkey. The 61st Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2010,
  2. Boston USA, Hepatology Vol 52; S1:697. 13. Guennoc X, Narbonne V, Joulin SJ, Pensec VP, Dougados M, Daures JP, et al. Is screening for Hepatitis B and Hepatitis C useful in patients with recent onset polyarthritis? The ESPOIR cohort study. Journal of Rheum 2009; 36: